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PCV79
ImPaCt Of GenerIC ClOPIdOGrel In the aCute COrOnary SyndrOme 
manaGement Of hOnG KOnG
Lee V.W.Y., Tsai R.P.C., Chow I.H.I., Yan B.P., Lam Y.Y.
The Chinese University of Hong Kong, Shatin, Hong Kong
Objectives: This study was conducted to compare health and cost outcomes utiliz-
ing either Ticagrelor versus Plavix in the management of acute coronary syndrome 
(ACS) patients, and impact of generic Clopidogrel used in Hong Kong. MethOds: A 
decision analytic model was used to perform a cost-effectiveness analysis of treat-
ing ACS patients for one year with Ticagrelor plus aspirin strategy compared with 
Plavix (or generic Clopidogrel) plus aspirin strategy from Hong Kong health care pro-
vider perspective. To estimate discounted (3%) lifetime costs, quality-adjusted life 
years (QALYs), and incremental cost-effectiveness ratios (ICERs). The health states 
in the model included patient in ACS without event, myocardial infarction (MI), and 
death from vascular cause. The model simulates a cohort of 45-year-old patients 
with ACS, and Markov cycle is one year. The time horizon was lifetime (85 years old). 
Event rates were adopted from the PLATO study, and the ACS registry in the Prince of 
Wales Hospital (PWH) in Hong Kong. Probabilistic sensitivity analyses using Monte 
Carlo simulations were conducted to assess parameter uncertainty. Results: 
Compared with the Plavix (or generic Clopidogrel) treatment strategy, the Ticagrelor 
treatment strategy for ACS, STEMI, and UA / NSTEMI patients were associated with 
ICERs of HK$ 34,441(35,304), HK$ 32,753(33,567), HK$ 39,343(40,417) (1US$ = 7.8HK$) 
per QALY gained, respectively. Ticagrelor treatment strategy was cost-effective over 
99% of the Monte Carlo simulation using a cost-effectiveness threshold of < 1x GDP 
per capita of Hong Kong. cOnclusiOns: The Ticagrelor strategy is considered cost-
effective at three times per capita GDP threshold compared with Plavix or generic 
Clopidogrel strategy in the management of ACS patients in Hong Kong. The impact 
of ICER values of generic clopidogrel compared with Plavix is not significant even 
the sextuple cost in Hong Kong.
PCV80
COSt effeCtIVeneSS analySIS Of mrI GuIded ablatIOn baSed On the 
deCaaf trIal
Singhal M.1, Biskupiak J.1, Ghate S.R.2, Marrouche N.1
1University of Utah, Salt Lake City, UT, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc., 
Ridgefield, CT, USA
Objectives: Catheter ablation, an expensive procedure with high Atrial Fibrillation 
(AF) recurrence rate, is indicated in patients refractory to drug therapy or in patients 
with drug tolerability issues. The study examines the CE of MRI-guided ablation 
vs. current standard of care (SoC) of ablating all eligible patients in preventing 
AF. MethOds: A decision tree model was developed with a payer perspective 
over a 1-year time horizon. Participants of the DECAAF trial (n= 260), prospective 
multicenter-blinded study, were categorized to Utah Stage I (19%), II (41%), III (31%), 
and Stage IV (9%) based on degree of atrial structural remodeling quantified using 
delayed enhancement MRI. Proportion of patients with post ablation AF recurrence 
for Utah Stage I-IV was 16.33%, 30.84%, 45.68%, and 58.33% respectively. Survival 
from outcomes was considered as effectiveness. Selective ablation was defined as 
ablating Stage I and II AF patients and medically managing Stage III and IV patients. 
Recurrence rates from the DECAAF trial and other costs and probabilities from the 
literature were used in the model. Probabilistic sensitivity analysis was conducted 
on all variables in the model. Results: The mean total per patient annual cost in 
the MRI-guided selective ablation cohort was $23,238 compared to $28,659 for the 
SoC ablates all cohorts. However, no significant – clinical or statistical, difference 
in effectiveness was observed. The higher cost of the ablate all cohort was associ-
ated with higher AF recurrence and costs of AF treatment. Probabilistic sensitivity 
analysis demonstrated the similar substantial difference between two procedures. 
The probability associated with AF recurrence in SoC was most sensitive varia-
ble. cOnclusiOns: MRI-guided selective ablation is economically beneficial with 
annual savings of $5,421 per person with same effectiveness compared to current 
SoC. Future research taking QoL and age into account is warranted to help payers 
assess the CE of ablation procedure in AF patients.
PCV81
an eCOnOmIC analySIS Of a hyPOthetICal Value-baSed InSuranCe 
deSIGn PrOGram uSInG the arChImedeS mOdel
Rael M.B.
Evidera, San Francisco, CA, USA
Objectives: Value-based insurance design (VBID) programs aim to encourage 
patient use of high value health care services, often with the goal of reducing 
overall cost. We investigate a hypothetical VBID program of copay elimination 
for statins to determine if it is cost saving and cost effective. MethOds: The 
Archimedes Model was used to simulate the outcomes of increased statin adher-
ence due to copay elimination. 10,000 individuals representative of US population 
who had been prescribed statins were modeled over a 10 year timeframe, sub-
jected to a two-arm virtual trial: one arm represents current care and the other 
arm represents copay elimination. Based on a literature review, statin adherence 
rates were increased by 3% in the copay elimination arm. Statin prices, based 
on generic prices, were $12/mo for Atorastatin80, $4/mo for Simvastatin80, and 
$3/mo for all other Simvastatin doses. Results: The VBID program failed to be 
cost saving, costing insurers $20 per person per year over the 10 year timeframe. 
The program saved 37 life years and 33 QALYs at a discounted cost of $66,000 per 
discounted QALY with 0.03 discount rate. For shorter timeframes the average 
cost remained constant and the program was even less cost effective. Follow-up 
simulations and analyses show that the program is increasingly cost effective in 
high risk subpopulations. For a population(n= 928) ages 60 to 70 with diabetes and 
prior MIs the program became cost saving after 12 years, having saved $94,000 
over 20 years. cOnclusiOns: The proposed VBID program failed to be cost sav-
ing because the benefit of increased statin adherence was small compared to the 
cost of copay elimination for all statin users. This failure to find cost savings is 
consistent with the published observational studies. To achieve cost savings VBID 
programs should be targeted according to individual risk.
PCV82
COSt-effeCtIVeneSS Of rIVarOxaban VerSuS dabIGatran fOr 
thrOmObOPrOPhylaxIS In tOtal hIP rePlaCement SurGery In the 
unIted StateS
Raval A.1, Vyas A.1, Kamal K.2
1West Virginia University, Morgantown, WV, USA, 2Duquesne University Mylan School of 
Pharmacy, Pittsburgh, WV, USA
Objectives: American College of Chest Physicians (ACCP) guideline recommends 
the use oral medication either rivaroxaban or dabigtran in patients who are under-
going major orthopedic surgery and decline injections. This study assessed the 
cost-effectiveness of rivaroxaban verus dabigatran for prevention of venous throm-
boembolism (VTE) and bleeding episode after total hip replacement (THR) surgery 
from Medicare perspective. MethOds: A 6-month decision-tree model was devel-
oped to compare the cost-effectiveness of rivaroxaban and dabigatran for THR. 
Treatment efficacy and safety data such as probabilities of distal and proximal deep 
vein thrombosis (DVT), symptomatic pulmonary embolism (PE), and major bleeding 
were derived from randomized controlled trials and systematic reviews. Cost of 
medications were derived from the Redbook (2012) and cost of DVT, PE and major/
minor bleeding episodes were based on diagnosis code related payment (2009). 
Guidelines consistent diagnosis procedure for VTE and current procedure terminol-
ogy (CPT) codes were utilized for determining procedure costs. All cost data was 
adjusted to 2012 dollars. A discount rate of 3% was applied to base-case analysis 
and sensitivity analysis were conducted to characterize uncertainty in the decision 
model. Results: The prophylaxis medication cost for rivoraxaban and dabigatran 
was $422.51 and $392.61, respectively for per person per event. The cost of treating 
major bleeding episode and VTE were $14,548.09 and $14,114.80, respectively per 
person per event. There were absence of any head-to-head studies comparing the 
dabigatran and rivaroxaban. Compared to standards heparin regimen, rates of bleed-
ing events did not differ significantly between dabigatran etexilate and rivaroxaban. 
However, the rates of having VTE event were higher in rivaroxaban compared to The 
prophylaxis treatment with dabigatran was $164.40 less costly than rivaroxaban for 
prevention of VTE and bleeding episode in patient undergoing THR. cOnclusiOns: 
Dabigatran and rivaroxaban share similar adverse events profiles, however, dabi-
gatran was found to be more cost-saving compared to rivaroxaban.
PCV83
the COSt-effeCtIVeneSS Of deteCtInG arrhythmIa WIth ImPlantable 
lOOP reCOrderS In the unIted State Of amerICa
Rogers J1, Chang S.2, Quiroz M.E.3, Madden T.3, Diamantopoulos A.4, Mollenkopf S.A.5
1Scripps Clinic Torrey Pines, La Jolla, CA, USA, 2Symmetron Limited, Elstree Herts, UK, 3Medtronic, 
Mounds View, MN, USA, 4Symmetron Limited, Elstree, UK, 5Medtronic, Inc., Mounds View, MN, 
USA
Objectives: To evaluate the cost-effectiveness of diagnosis with an ILR following 
Standard Testing (ST) after a syncopal event from a United States payer perspec-
tive. MethOds: This analysis considers all costs of diagnosis via ST and ILR, the 
costs and consequences of recurrent syncope, and the cost of arrhythmia treat-
ment following diagnosis. A Markov model was developed to reflect the recurrence 
of syncopal events in undiagnosed patients. Due to documented differences in 
the prevalence of arrhythmia between patients with suspected arrhythmia and 
patients with unexplained syncope we considered the two populations separately, 
each over a 10-year time horizon. All costs and consequences were discounted at 
a 3% annual rate. Results: The results are similar for suspected arrhythmia and 
unexplained syncope. In the suspected arrhythmia population, the incremental cost 
of the ILR strategy is $14,712. The incremental Quality Adjusted Life Years (QALY) are 
estimated to be between 0.2806 and 0.4282, and the incremental cost-effectiveness 
ratio (ICER) is between $34,400 and $52,400. The syncopal events avoided with ILR 
are 402 per 1,000 patients. In the unexplained syncope population the incremental 
costs and effects are lower compared to the previous case: $13,800, and between 
0.2174 and 0.3317 QALYs gained. The ICER is between $41,600 and $63,500 per QALY 
gained. The number of syncopal events avoided with ILR is 311 per 1,000 patients. 
In 1,000 patients the ILR strategy is estimated to identify between 300 and 380 more 
arrhythmia cases compared to ST in the two populations. cOnclusiOns: When 
considering all costs in combination with the syncopal events avoided and quality 
of life (QoL), ILR arrhythmia diagnosis is a cost-effective alternative to ST. The use 
of ILR increases the diagnostic yield in both populations and guides treatment in 
more patients compared to ST.
PCV84
COSt effeCtIVeneSS eValuatIOn Of aPIxaban, dabIGatran 
rIVarOxaban and WarfarIn fOr PreVentIOn Of trOmbOembOlISm In 
PatIentS WIth atrIal fIbrIllatIOn In trInIdad and tObaGO
Garita M.1, Peralta M.1, Dookie T.A.2
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Westshore Medical Centre, 
Port-of-Spain, Trinidad and Tobago
Objectives: The main goal of treatments for AF is stroke prevention since the 
annual risk of stroke is 5–6 times greater in patients with AF than in people with 
a normal heart rhythm. [1] The incidence of AF increases from less than 0.1% per 
year in those under 40 years old to exceed 1.5% per year in women and 2% in 
men older than 80. [2] This study assesses the cost-effectiveness (CE) of Apixaban 
versus other anticoagulation therapies for prevention on NVAF, from the private 
health care perspective. MethOds: A Markov decision-tree model was made to 
compare costs and effectiveness of Warfarin (5 mg/24 hours), Apixaban (5 mg/12 
hours), Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 
mg/24 hours) in a simulated cohort of 1000 patients with AF. Effectiveness meas-
ures were: stroke, bleeding, myocardial infarction (MI) rates and deaths. Local costs 
were gathered from Trinidad’s Private Health System databases (US$, 2013) and only 
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direct medical costs were considered. [3] The model used a lifetime horizon with 
a 5% discount. Results: Of all therapies, Apixaban is the only one that improved 
outcomes in number of Strokes (4), MI (3), Bleedings (85) and Systemic Embolism 
events (1) prevented when compared to Warfarin. Overall costs were US$19007.24, 
US$24615.16, US$24137.36, US$23510.21, and US$25067.11 for Warfarin, Apixaban, 
Dabigatran 110 mg, Dabigatran 150 mg and Rivaroxaban respectively. In terms of 
QALY’s, Apixaban earned the highest amount with 5.736 while Warfarin has the low-
est reported of 5.566. In the CE incremental analysis, Apixaban was a cost-effective 
alternative to other anticoagulants. According to Trinidad’s Willingness to Pay (3 
GPB per capita), Apixaban obtained the highest probability of being cost-effective 
(70%). cOnclusiOns: Apixaban is a Cost-Effective option for the Trinidad’s Private 
Health System.
PCV85
COSt effeCtIVeneSS Of aPIxaban COmaPred tO aSPIrIn In PatIentS 
WIth atrIal fIbrIllatIOn
Ademi Z., Pasupathi K., Liew D.
University of Melbourne, Melbourne, Australia
Objectives: To determine the cost-effectiveness of apixaban compared to aspi-
rin to prevent thromboembolic events in patients with atrial fibrillation who are 
unsuitable or intolerant of warfarin therapy, from an Australian health care perspec-
tive. MethOds: By extrapolating data from the Apixaban Versus Acetylsalicylic 
acid to prevent Stroke in Atrial Fibrillation (AVERROSE) trial, a Markov model with 
yearly cycles was developed to simulate the costs and effects of apixaban compared 
to aspirin over 10 years. The model comprised five health states: ‘Alive without 
thromboembolic disease (stroke, myocardial infarction and other systemic embo-
lism) nor major bleeding (MB)’; ‘Alive with thromboembolic disease, but without 
prior MB’; ‘ Alive without thromboembolic disease, but with prior MB’; ‘Alive with 
thromboembolic disease and prior MB’; and ‘Dead’. Costs, from an Australian health 
care perspective, were estimated from published sources. The main outcome of 
interest was incremental cost-effectiveness ratio (ICER) per quality adjusted life 
year (QALY) saved and per year of life saved (YoLS). Costs and benefits were dis-
counted at 5.0% per annum. Results: For each patient followed-up over 10 years, 
the model predicted that compared to aspirin, apixaban would lead to 0.19 YoLS 
(discounted) and 0.20 QALYs saved (discounted), at a net cost of AUD $5,025 (dis-
counted). This equated to ICERs of AUD $27,090 per YoLS and AUD $25,095 per QALY 
saved. One way and probabilistic sensitivity analyses indicated the results to be 
robust. cOnclusiOns: Compared to aspirin, apixaban is likely to be cost-effective 
in preventing thromboembolic disease among patients with atrial fibrillation who 
are intolerant to warfarin.
PCV86
CardIOVaSCular SurGery PathWay mICrOSImulatIOn frameWOrK tO 
Study the health eCOnOmICS Of CleVIdIPIne
Schwenkglenks M.1, Wang Y.2, Crothers T.A.2, Pfeil A.M.1, Plent S.2
1University of Basel, Basel, Switzerland, 2The Medicines Company, Parsippany, NJ, USA
Objectives: Clevidipine, a short-acting, intravenous dihydropyridine calcium chan-
nel blocker, is easily titratable to achieve the desired blood pressure (BP). The ECLIPSE 
trials compared the safety and efficacy of clevidipine to sodium nitroprusside, nitro-
glycerin, and nicardipine during the perioperative period in cardiac surgery patients. 
We sought to gain an initial understanding of economic properties. MethOds: A 
decision-analytic microsimulation framework was defined to follow patients from 
hospital admission; assigned characteristics reflected the pooled ECLIPSE popula-
tions (1,511 coronary artery bypass graft and/or valve surgery patients aged 19-89 
years). Exploratory multivariate regression analyses of the ECLIPSE data identified 
potential clinical and economic effects of clevidipine. Additional inputs came from 
administrative databases and published sources. Costs were assessed from a US 
health system perspective. Unit costs for intensive care and normal ward covered 
room and board costs only. Economic endpoints included cost per death avoided 
at day 30 and cost per quality-adjusted life year (QALY) gained. A life-long time 
horizon was adopted for the latter; costs and effects were discounted by 3% per 
year. Results: BP control was significantly associated with time to extubation and 
30-day occurrence of bleeding, renal insufficiency, death; associations with other 
clinical events, length of stay were non-significant. At day 30, clevidipine dominated 
comparators. Costs ranged from USD14,718 (clevidipine) to USD15,787 (nicardipine). 
Probability of survival varied slightly between agents; from 96.8% (clevidipine) to 
96.4% (sodium nitroprusside). For the life-long time horizon, clevidipine showed 
an incremental cost-effectiveness of USD10,863 per QALY gained versus sodium 
nitroprusside. Nitroglycerin and nicardipine were dominated. cOnclusiOns: Our 
framework provides a flexible basis for assessing economic properties of clevidipine 
use in cardiac surgery. The effects implemented to-date, driving economic results, 
come from unplanned, exploratory analyses and require independent, ideally 
prospective verification. Current numerical results, including cost savings, should 
therefore be interpreted as indicative of potential but highly tentative.
PCV87
COSt effeCtIVeneSS analySIS Of the threShOld fOr InItIal 
hyPertenSIOn treatment- a marKOV Study fOllOWInG the JnC8 
GuIdelIne
Jiao T.
University of Utah, Salt Lake City, UT, USA
Objectives: Recently, “2014 evidence-based guideline for the management of high 
blood pressure in adults” was published by the Eighth Joint National Committee 
(JNC 8), in which the threshold of initiate pharmacologic treatment to lower blood 
pressure at systolic blood pressure (SBP) was increased from 140 to 150 mmHg. 
Considering the scarcity of economic evaluation of threshold for initial hyperten-
sion treatment, the aim of this study was to evaluate whether the new threshold of 
initial hypertension treatment is cost-effective compared to the former one from a 
third party payer perspective. MethOds: A state-transitional model was built using 
published evidence comparing the quality adjusted life years (QALYs) patients 60 
years or older gained using different threshold of initial hypertension treatment. 
The QALYs and occurrence of CVD were used as primary and secondary outcome. 
The model used a life-time framework adopting a third-party payer’s perspective. 
Incremental cost-effectiveness ratio (ICER) between groups was calculated in U.S. 
dollars per QALY gained. Both one-way sensitivity analyses and probabilistic sen-
sitivity analysis were conducted to explore the uncertainty of variables. Results: 
The ICER for the base case of the new guideline versus the original one was 30,298 
U.S. dollars per QALY gained. Other than age of patients, there is no variable could 
significantly influence results. There would be a 32% of more effective and less 
costly using new guideline threshold, and overall 83% chance of being cost-effective 
compared with the original one. cOnclusiOns: The results indicated that it high 
likely that the new guideline of threshold for initial hypertension treatment is cost-
effective than the original one, which means for patients older than 60 years diag-
nosed with hypertension, the initial anti-hypertension treatment could be given 
till the SBP comes to 150 mmHg.
PCV88
COSt-effeCtIVeneSS analySIS Of ambrISentan VerSuS bOSentan In 
the treatment Of PatIentS WIth PulmOnary arterIal hyPertenSIOn 
funCtIOnal ClaSS III
Ochoa F.1, Rojas L.2, Romero M.3
1Salutia Foundation, Bogota, Colombia, 2Universidad de Bogota Jorge Tadeo Lozano, Bogota, 
Colombia, 3Fundacion Salutia, Bogota, Colombia
Objectives: Assess the cost-effectiveness of ambrisentan versus bosentan for 
treatment of pulmonary arterial hypertension in patients with OMS functional class 
III for knowing which treatment has superior efficiency. MethOds: We performed 
a cost-effectiveness analysis using a Markov model. It has involved the treatment of 
a patient older than 50 years, which has continued until he had completed 80 years 
and compared the results obtained in a patient treated with bosentan and another 
patient treated with ambrisentan. The transition probabilities between different 
health states considered in the model were taken from the literature review and 
estimated for each cycle of the model. To evaluate the drug price effect and vari-
ations of effectiveness on results, we developed a sensitivity analysis Montecarlo 
type. Results: In the base case, the ambrisentan was more cost-effective than 
bosentan, with an approximate cost of $ 53.146,41 (USD) for each year of life free 
of disease versus $ 61.040,93 (USD) for year of life free of disease for bosentan. 
The incremental cost-effectiveness ratio by patient was $ 143.505,23 (USD). The 
variable that more affected the final result was the drug price. Sensitivity analysis 
showed that the model is robust, and to changes in price and efficacy of the drug 
the results are stable, and ambrisentan remains cost-effective. ConclusionSWith the 
data obtained in the study the use of ambrisentan in the treatment of pulmonary 
arterial hypertension in Colombia is presented as an efficient alternative despite 
currently the bosentan is reimbursed
PCV89
COSt-effeCtIVeneSS Of aPIxaban aGaInSt Current Standard Of Care 
fOr StrOKe PreVentIOn In atrIal fIbrIllatIOn In ChIle
Vallejos C., Lanas Zanetti F., Castro C., Bustos L.
Universidad de La Frontera, Temuco, Chile
Objectives: Acenocoumarol, a vitamin K antagonist (VKA) is the standard of 
care for stroke prevention in patients with atrial fibrillation (AF) in Chile. While 
ARISTOTLE enrolled warfarin as a comparator, evidence is deemed applicable to 
patients treated with acenocoumarol (called as VKA hereafter) in Latin America and 
Southern Europe. Nevertheless, Apixaban is the only novel oral anticoagulant that 
has demonstrated significant benefit in terms of efficacy and safety against war-
farin in ARISTOTLE. The aim of this study is to estimate the cost-effectiveness (CE) 
of Apixaban versus VKA in Non Valvular Atrial Fibrillation (NVAF) from the public 
payer perspective in Chile. MethOds: A Markov model was adapted to evaluate 
the clinical and economic impact of Apixaban compared to VKA in VKA-suitable 
population over lifetime. Effectiveness data were derived from the original clinical 
trials. Clinical events captured include ischemic and hemorrhagic stroke (further 
categorized as mild, moderate or severe), intracranial hemorrhage (ICH), other major 
bleed, clinically relevant non-major bleed, myocardial infarction, cardiovascular 
hospitalization and deaths. Benefit assessment was conducted using a patient pref-
erence study using EQ-5D. The model was imputed the parameters of local costs and 
utilities, and Chilean epidemiology data. Associated direct medical costs were taken 
from local databases; discounted at 3.5% per year, and expressed in 2013 CLP$ as of 
July. Results: The incremental cost of treating a patient with Apixaban vs VKA was 
CLP$ 1,964,424, providing an incremental effectiveness of 0.537 QALY. Therefore, the 
cost per QALY gained is CLP$ 3,967,325. Tornado analysis shows that results are most 
sensitive to stroke risk for Apixaban, followed by ICH risk for VKA cOnclusiOns: 
Using accepted threshold for cost effectiveness of CLP$ 9,552,500 for Chilean market 
(1 GDP/capita), Apixaban was deemed as a very cost effective alternative to VKA for 
stroke prevention in non-valvular AF patients in Chile.
PCV90
COSt-effeCtIVeneSS Of rIVarOxaban fOr the treatment Of PulmOnary 
embOlISm In Canada
Levac B.1, Marrie J.1, Chin W.2, Hassan F.3, Bamber L.4, McLeod E.J.3
1Bayer Inc., Toronto, ON, Canada, 2ILEX Consulting Inc., Canada, 3IMS Health, London, UK, 4Bayer 
Healthcare, Germany
Objectives: Current standard treatment of pulmonary embolism (PE) in Canada 
involves a low molecular weight heparin (LMWH) and vitamin K antagonist (VKA). 
However, such treatment has limitations. Rivaroxaban, an oral factor Xa inhibitor, 
was recently approved approved by Health Canada for the treatment of venous 
thromboembolic events (VTE - deep vein thrombosis [DVT], pulmonary embolism 
[PE]) and prevention of recurrent DVT and PE. EINSTEIN-PE compared rivaroxaban 
to enoxaparin/VKA for 3, 6 or 12 months of treatment post-PE. Rivaroxaban was 
